Soluble Interleukin-6 (IL-6) Receptor/IL-6 Fusion Protein Enhances in Vitro Differentiation of Purified Rat Oligodendroglial Lineage Cells

We investigated the effects of a chimeric protein (IL6RIL6 chimera) containing interleukin-6 (IL-6) fused to its soluble receptor (sIL-6R) on the proliferation and/or differentiation of rat oligodendrocyte progenitor cells (OPCs) and on oligodendrocyte survival. Exposure of OPCs to IL6RIL6 chimera for 48 h induced a dose-dependent decrease of bromodeoxyuridine (BrdU) incorporation. IL6RIL6 chimera treatment for 48 h also strongly increased the reduction of the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) by mitochondrial enzymes and enhanced oligodendrocyte staining with a mitochondrial fluorescent dye. A strong, dose-dependent increase in the number and length of processes immunostained for early (galactocerebroside) or late (myelin basic protein) oligodendrocyte differentiation markers was revealed after OPC treatment with IL6RIL6 chimera for 2-7 days, respectively. Moreover, treatment with IL6RIL6 chimera improved oligodendrocyte survival. The chimera-induced increase of oligodendrocyte arborization was mimicked, although with lower efficacy, by ciliary neurotrophic factor (CNTF) but not by IL-6 and was reduced in the presence of a gp130 soluble peptide which is able to inhibit the gp130-mediated signals of the IL-6/sIL-6R complex. Oligodendrocyte treatment with IL6RIL6 chimera for 30 min induced both signal transducer and the activator of transcription-1 (STAT-1) and STAT-3 phosphorylation and nuclear translocation. We conclude that, by interacting with membrane gp130 and possibly by activating Janus kinase/STAT pathways, IL6RIL6 chimera induces OPCs to differentiate into mature oligodendrocytes, promotes their survival, and could deserve investigation as a therapeutic strategy for enhancing remyelination.

[1]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[2]  Anil K. Kamaraju,et al.  Pax3 Down-regulation and Shut-off of Melanogenesis in Melanoma B16/F10.9 by Interleukin-6 Receptor Signaling* , 2002, The Journal of Biological Chemistry.

[3]  L. Calzà,et al.  Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Rudick,et al.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. , 2002, The New England journal of medicine.

[5]  N. Déglon,et al.  Neuroprotective effect of interleukin‐6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome , 2001, European Journal of Neuroscience.

[6]  M. Schwartz,et al.  Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility , 2001, Journal of Neuroimmunology.

[7]  A. Kumar,et al.  Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin‐6 receptor–interleukin‐6 chimera , 2001, Journal of neuroscience research.

[8]  T. Olsson,et al.  Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis , 2001, Journal of Neuroimmunology.

[9]  C. Richter-Landsberg,et al.  Organization and functional roles of the cytoskeleton in oligodendrocytes , 2001, Microscopy research and technique.

[10]  Richard Reynolds,et al.  The oligodendrocyte precursor cell in health and disease , 2001, Trends in Neurosciences.

[11]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[12]  S. Chevalier,et al.  CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex , 2000, Nature Neuroscience.

[13]  M. Noble,et al.  Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Raff,et al.  Long-Term Culture of Purified Postnatal Oligodendrocyte Precursor Cells , 2000, The Journal of cell biology.

[15]  L. Decker,et al.  Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination , 1999, The European journal of neuroscience.

[16]  Y. Saeki,et al.  IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35–55 induced experimental autoimmune encephalomyelitis , 1999, Journal of Neuroimmunology.

[17]  S. Rose-John,et al.  Neural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors , 1999, The European journal of neuroscience.

[18]  M. Revel,et al.  Induction of myelin gene expression in Schwann cell cultures by an interleukin‐6 receptor‐interleukin‐6 chimera , 1999, FEBS letters.

[19]  C. De-Fraja,et al.  Signalling through the JAK–STAT pathway in the developing brain , 1999, Trends in Neurosciences.

[20]  A. Nagler,et al.  The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(-/low) cells capable of repopulating severe combined immunodeficiency mice. , 1999, Blood.

[21]  B. Hilliard,et al.  IL-6-deficient mice are resistant to experimental autoimmune encephalomyelitis: roles of IL-6 in the activation and differentiation of autoreactive T cells. , 1998, Journal of immunology.

[22]  M. Mehler,et al.  Differentiation of Oligodendroglial Progenitors Derived from Cortical Multipotent Cells Requires Extrinsic Signals Including Activation of gp130/LIFβ Receptors , 1998, The Journal of Neuroscience.

[23]  J. de Vellis,et al.  Oligodendroglial survival factors, PDGF‐AA and CNTF, activate similar JAK/STAT signaling pathways , 1998, Journal of neuroscience research.

[24]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[25]  K. Frei,et al.  IL‐6‐deficient mice resist myelin oligodendrocyte glycoprotein‐induced autoimmune encephalomyelitis , 1998, European journal of immunology.

[26]  A. Ben-nun,et al.  Interleukin‐6 functions in autoimmune encephalomyelitis: a study in gene‐targeted mice , 1998 .

[27]  Y. Saeki,et al.  IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. , 1998, International immunology.

[28]  A. Nagler,et al.  Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. , 1997, European cytokine network.

[29]  C. Hock,et al.  Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients , 1997, Neuroscience Letters.

[30]  P. Gallois,et al.  Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. , 1997, Acta neurologica Belgica.

[31]  G. D. Lange,et al.  High Density Distribution of Endoplasmic Reticulum Proteins and Mitochondria at Specialized Ca2+ Release Sites in Oligodendrocyte Processes* , 1997, The Journal of Biological Chemistry.

[32]  H. Link,et al.  High IL-6 and low IL-10 in the central nervous system are associated with protracted relapsing EAE in DA rats. , 1997, Journal of neuropathology and experimental neurology.

[33]  G. Guazzi,et al.  IL-6 detection in multiple sclerosis brain , 1997, Journal of the Neurological Sciences.

[34]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[35]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[36]  G. Levi,et al.  Reversible Inhibitory Effects of Interferon‐γ and Tumour Necrosis Factor‐α on Oligodendroglial Lineage Cell Proliferation and Differentiation In Vitro , 1996 .

[37]  Vos Jp,et al.  Regulation of oligodendrocyte cell survival and differentiation by ciliary neurotrophic factor, leukemia inhibitory factor, oncostatin M, and interleukin-6. , 1996 .

[38]  E. Barbarese,et al.  Morphological organization of oligodendrocyte processes during development in culture and in vivo. , 1996, Developmental neuroscience.

[39]  S. Kirischuk,et al.  Preferential localization of active mitochondria in process tips of immature retinal oligodendrocytes. , 1995, Neuroreport.

[40]  A. Gard,et al.  Oligodendroblasts distinguished from O-2A glial progenitors by surface phenotype (O4+GalC-) and response to cytokines using signal transducer LIFR beta. , 1995, Developmental biology.

[41]  W. Cowden,et al.  Cytokines and Murine Autoimmune Encephalomyelitis: Inhibition or Enhancement of Disease with Antibodies to Select Cytokines, or by Delivery of Exogenous Cytokines Using a Recombinant Vaccinia Virus System , 1995, Scandinavian journal of immunology.

[42]  Moses Rodriguez,et al.  Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. , 1994, Journal of immunology.

[43]  J. de Vellis,et al.  Regulation of an oligodendrocyte progenitor cell line by the interleukin‐6 family of cytokines , 1994, Glia.

[44]  P. Heinrich,et al.  Soluble receptors for cytokines and growth factors: generation and biological function. , 1994, The Biochemical journal.

[45]  M. Noble,et al.  Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. , 1994, Development.

[46]  S. Akira,et al.  Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Marunouchi,et al.  Expression of cytokine receptors in cultured neuronal and glial cells , 1993, Neuroscience Letters.

[48]  G. Yancopoulos,et al.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. , 1993, Blood.

[49]  B. Barres,et al.  Multiple extracellular signals are required for long-term oligodendrocyte survival. , 1993, Development.

[50]  J. Louis,et al.  CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death , 1993, Science.

[51]  J. McCubrey,et al.  Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. , 1993, Journal of immunological methods.

[52]  J. Bazan.  Neuropoietic cytokines in the hematopoietic fold , 1991, Neuron.

[53]  G. Levi,et al.  Heterotypic and homotypic cellular interactions influencing the growth and differentiation of bipotential oligodendrocyte-type-2 astrocyte progenitors in culture. , 1991, Developmental biology.

[54]  A. Fontana,et al.  Interleukin-6 is elevated in plasma in multiple sclerosis , 1991, Journal of Neuroimmunology.

[55]  J. Bazan,et al.  Structural design and molecular evolution of a cytokine receptor superfamily. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[56]  O. Bogler,et al.  Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Raff,et al.  Extracellular matrix-associated molecules collaborate with ciliary neurotrophic factor to induce type-2 astrocyte development , 1990, The Journal of cell biology.

[58]  G. Levi,et al.  Differentiation of cerebellar bipotential glial preecurosrs into oligodendrocytes in primary culture: Development profile of surface antigens and mitotic activity , 1987, Journal of neuroscience research.

[59]  M. Raff,et al.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium , 1983, Nature.